Article
Oncology
Laura Streit, Sophie Moog, Sylvain Hugel, Marion Rame, Emeline Tanguy, Virginie Andry, Herbert A. Schmid, Laurent Brunaud, Florence Bihain, Claire Nomine-Criqui, Yannick Goumon, Stephanie Lacomme, Sandra Lomazzi, Michel Vix, Didier Mutter, Nicolas Vitale, Stephane Ory, Stephane Gasman
Summary: NETs like pheochromocytoma can cause severe symptoms and life-threatening conditions. Treatment with somatostatin analogues may help inhibit the secretion of catecholamines. The study found that SOM230 could effectively inhibit catecholamine secretion and be considered a potential anti-secretory treatment for patients with pheochromocytoma.
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gerald Raverot, Laura De Marinis
Summary: This review provides an overview of the second-line therapies for acromegaly, summarizing the evidence on clinical, molecular, and morphological aspects that can predict the response to these treatments and advocating for a patient-tailored therapeutic approach in clinical practice.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Richard A. Feelders, Maria Fleseriu, Pinar Kadioglu, Marie Bex, Deyanira Gonzalez-Devia, Cesar Luiz Boguszewski, Dilek Gogas Yavuz, Heather Patino, Alberto M. Pedroncelli, Ricardo Maamari, Arghya Chattopadhyay, Beverly M. K. Biller, Rosario Pivonello
Summary: The study evaluated the efficacy and safety of pasireotide alone or combined with cabergoline in patients with Cushing's disease. The addition of cabergoline in patients with persistently elevated cortisol levels on maximum tolerated doses of pasireotide was shown to be effective and well-tolerated in enhancing control of hypercortisolism in some CD patients.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Monica R. Gadelha, Murray B. Gordon, Mirjana Doknic, Emese Mezosi, Miklos Toth, Harpal Randeva, Tonya Marmon, Theresa Jochelson, Rosa Luo, Michael Monahan, Ajay Madan, Christine Ferrara-Cook, R. Scott Struthers, Alan Krasner
Summary: This study aimed to evaluate the change in insulin-like growth factor I (IGF-I) levels in patients who switched from octreotide or lanreotide monotherapy to paltusotine. The results showed that once-daily oral paltusotine was effective in maintaining IGF-I levels in patients and was well tolerated.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Monica Gadelha, Nelma Veronica Marques, Christhiane Fialho, Cristiane Scaf, Elisa Lamback, Ximene Antunes, Erica Santos, Jaqueline Magalhaes, Luiz Eduardo Wildemberg
Summary: This study retrospectively analyzed the long-term efficacy and safety of Pasireotide, a somatostatin receptor ligand, in the treatment of acromegaly patients. The results showed that Pasireotide provided clinical benefit and was well tolerated for over 11 years of treatment in acromegaly patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Amit Akirov, Alexander Gorshtein, Idit Dotan, Nariman Saba Khazen, Yulia Pauker, Michal Gershinsky, Ilan Shimon
Summary: The study shows that pasireotide LAR has tolerable and long-term significant biochemical response in acromegaly patients with potential delayed effect on IGF-1 normalization. Patients with pre-diabetes or diabetes mellitus history have an increased risk of developing new-onset diabetes during treatment with pasireotide.
Article
Endocrinology & Metabolism
Maria Fleseriu, Mark Molitch, Alexander Dreval, Yulia Pokramovich, Irina Bondar, Yury Poteshkin, Djuro Macut, Barbara Obermayer-Pietsch, Yossi Gilgun-Sherki, Asi Haviv, Nienke Biermasz, Christian J. Strasburger
Summary: The study assessed the long-term efficacy and safety of oral octreotide capsules in patients with acromegaly. The results showed that the capsules were noninferior to injectable somatostatin receptor ligands, and transitioning from injectables to oral capsules improved symptoms.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Andrea Giustina, Luigi di Filippo, Melin M. Uygur, Stefano Frara
Summary: A personalized approach to acromegaly treatment, utilizing novel clinical and molecular biomarkers, has shown promising results in predicting responsiveness to second-line medical treatments. Integrating these findings into existing guidelines may significantly improve the management of difficult acromegaly patients.
Article
Endocrinology & Metabolism
Antonella Giampietro, Sara Menotti, Sabrina Chiloiro, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: This study reports three cases of resistant acromegaly treated with a de-escalation approach using pasireotide LAR. The results showed that de-escalation treatment with pasireotide LAR may allow a greater proportion of patients to achieve control of acromegaly, especially in clinically aggressive cases. Although there may be a risk of hyperglycemia, it can be controlled with oral antidiabetic medications.
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonella Giampietro, Federica Mirra, Federico Donfrancesco, Tommaso Tartaglione, Pier Paolo Mattogno, Flavia Angelini, Lauretti Liverana, Marco Gessi, Anile Carmelo, Guido Rindi, Andrea Giustina, Maria Fleseriu, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: The study investigated predictors of response to Pegvisomant and Pasireotide LAR in acromegaly patients, finding that factors such as tumor extension, Ki67-Li levels, and IGF-I levels may impact treatment efficacy.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Susan L. Samson, Lisa B. Nachtigall, Maria Fleseriu, Mojca Jensterle, Patrick J. Manning, Atanaska Elenkova, Mark E. Molitch, William H. Ludlam, Gary Patou, Asi Haviv, Nienke R. Biermasz, Andrea Giustina, Christian J. Strasburger, Laurence Kennedy, Shlomo Melmed
Summary: This study reports the long-term durability of therapeutic response in adults with acromegaly receiving oral octreotide capsules (OOC). The results show that patients maintained a biochemical response while receiving OOC and no new adverse events were observed with prolonged OOC exposure.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Monica R. Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki
Summary: This article discusses the future perspectives of currently available SRLs, including the use of biomarkers of response and precision medicine, new formulations of these SRLs, and new drugs under development. Precision medicine based on biomarkers of response can help improve treatment decision-making and response rates. New formulations may improve patients' adherence to treatment and quality of life. New drugs may present higher efficacy than currently available drugs.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Maria Fleseriu, Dagmar Fuehrer-Sakel, Aart J. van der Lely, Laura De Marinis, Thierry Brue, Joli van der Lans-Bussemaker, Judith Hey-Hadavi, Cecilia Camacho-Hubner, Michael P. Wajnrajch, Srinivas Rao Valluri, Andrew Anthony Palladino, Roy Gomez, Roberto Salvatori
Summary: The long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY demonstrate overall favorable benefit-to-risk profile and high efficacy of PEGV. IGF1 normalization rate improved over time, with fewer complications such as abnormal liver function and pituitary tumor growth.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Sofie Eline Tollefsen, Ole Solheim, Patricia Mjones, Sverre Helge Torp
Summary: Meningioma is a common brain tumor without approved specific drugs. This study aims to compile the current insights of somatostatin analogs for treating patients with meningioma. A systematic search was conducted, and 17 eligible studies were evaluated. Although the efficacy of somatostatin analogs remains unclear, some studies suggest that they may be a last-option treatment for severely ill-patients. However, a controlled study or randomized clinical trial is needed to establish their efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Przemyslaw Witek, Marek Bolanowski, Katarzyna Szamotulska, Agnieszka Wojciechowska-Luzniak, Aleksandra Jawiarczyk-Przybylowska, Marcin Kaluzny
Summary: The study aimed to evaluate the glucose metabolism in acromegaly patients treated with pasireotide LAR, showing a decrease in GH levels but worsening of metabolic status with increased HbA1c levels, necessitating intensifying antihyperglycemic treatment.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Editorial Material
Transplantation
Yassine Laghrib, Christophe De Block, Daniel Abramowicz, Rachel Hellemans
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Endocrinology & Metabolism
Christophe De Block, Clifford Bailey, Carol Wysham, Andrea Hemmingway, Sheryl Elaine Allen, Jennifer Peleshok
Summary: Tirzepatide is a novel drug that improves glycemic control and aids weight loss in patients with type 2 diabetes. It also shows potential for treatment of other conditions. Clinical trials have demonstrated that Tirzepatide has better effects on reducing glycated hemoglobin and body weight compared to GLP-1 receptor agonists, with a lower risk of hypoglycemia.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Caro Minschart, Astrid Lammertyn, Paul Van Crombrugge, Carolien Moyson, Johan Verhaeghe, Sofie Vandeginste, Hilde Verlaenen, Chris Vercammen, Toon Maes, Els Dufraimont, Nele Roggen, Christophe De Block, Yves Jacquemyn, Farah Mekahli, Katrien De Clippel, Annick Van Den Bruel, Anne Loccufier, Annouschka Laenen, Roland Devlieger, Chantal Mathieu, Katrien Benhalima
Summary: The level of gestational weight gain (GWG) during pregnancy is associated with adverse pregnancy outcomes in women with gestational diabetes (GDM) compared to women with normal glucose tolerance (NGT). Low GWG below recommended levels frequently occurs in GDM women without increased risk for adverse outcomes. Excessive GWG is associated with increased risk for neonatal hypoglycemia and worse metabolic profile postpartum in GDM women, and with higher rates of instrumental delivery and larger infants in NGT women.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Andrology
Jolijn Van Cauwenberghe, Christophe De Block, Dirk Vanderschueren, Leen Antonio
Summary: Current available evidence suggests that traditional antidiabetic drugs have limited effects on testosterone levels, while GLP-1 receptor analogues show promising results for improving both testosterone levels and obesity in men with low testosterone levels. However, further studies are needed due to limited data and heterogeneous study groups.
Article
Immunology
Julie Vandewalle, Aster K. Desouter, Bart J. van der Auwera, Sylvie Tenoutasse, Pieter Gillard, Christophe De Block, Bart Keymeulen, Frans K. Gorus, Mark van de Casteele, Belgian Diabetes Registry
Summary: The HLA region is the major genetic risk determinant of Type 1 diabetes. Non-HLA loci, such as INS, SH2B3, PTPN2, PTPN22, CTLA4, CLEC16A, and IL2RA, may also contribute to the genetic risk by impacting the progression of asymptomatic autoimmunity. In this study, the researchers investigated the relationship between SNPs in these susceptibility loci and the progression from single to multiple autoantibody positivity, as well as the development of clinical diabetes. They found that certain genotypes in CTLA4 and CLEC16A were associated with accelerated progression from single to multiple autoantibody positivity, but their effects were limited to specific conditions. The interaction between CTLA4 and HLA-DQ2/DQ8 was found to override the effect of HLA-DQ2/DQ8 alone. The study also showed that SH2B3 genotype was protective for HLA-DQ8 positive subjects, while CTLA4 genotype was a minor independent risk factor for progression towards clinical diabetes. The findings suggest that non-HLA polymorphisms impact the progression of islet autoimmunity in specific ways and may have implications for risk assessment and prevention trials in at-risk groups.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2023)
Article
Endocrinology & Metabolism
Sara Charleer, Christophe De Block, Nancy Bolsens, Liesbeth Van Huffel, Frank Nobels, Chantal Mathieu, Pieter Gillard
Summary: This study investigates the impact of nationwide reimbursement of intermittently scanned continuous glucose monitoring (isCGM) on adults with type 1 diabetes with impaired or normal awareness of hypoglycemia over 24 months. The results show sustained improvement in severe hypoglycemia, work absenteeism, and hypoglycemia fear after isCGM reimbursement, with increased treatment satisfaction. isCGM is a valuable tool under long-term real-world conditions regardless of hypoglycemia awareness level.
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Margaretha M. Visser, Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, Nele Myngheer, Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard
Summary: The ALERTT1 study compared the benefits of switching from isCGM to rtCGM in adults with type 1 diabetes. The results showed that rtCGM improved glycemic control and reduced hypoglycemia worry significantly up to 24 months.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Lore Raets, Kim Van Hoorenbeeck, Toon Maes, Chris Vercammen, Christophe De Block, Eveline Dirinck, Inge Van Pottelbergh, Katrien Wierckx, Annouschka Laenen, Annick Bogaerts, Chantal Mathieu, Katrien Benhalima
Summary: The Belgian Diabetes in Pregnancy follow-up study (BEDIP-FUS) aims to investigate the impact of BMI, adiposity, and glucose intolerance on the metabolic profile and future risk for T2D in women and offspring after a five-year period. The study involves recruiting 375 women-offspring pairs based on the results of glucose challenge and oral glucose tolerance tests during pregnancy. The primary outcomes measured are glucose intolerance in mothers and BMI z-score in offspring. The study is important for individualizing follow-up care for women with different degrees of hyperglycemia during pregnancy and their offspring.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Athena Philis-Tsimikas, Vanita R. Aroda, Christophe De Block, Liana K. Billings, Andreas Liebl, Ramsathish Sivarathinasami, John M. D'Cruz, Ildiko Lingvay
Summary: This post hoc analysis compared the effects of two treatment methods on blood glucose stability in patients with type 2 diabetes. The results showed that insulin degludec/liraglutide combination therapy was more effective than insulin glargine 100 units/mL treatment.
JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY
(2023)
Article
Endocrinology & Metabolism
Caro Minschart, Nele Myngheer, Toon Maes, Christophe De Block, Inge Van Pottelbergh, Pascale Abrams, Wouter Vinck, Liesbeth Leuridan, Sabien Driessens, Chantal Mathieu, Jaak Billen, Christophe Matthys, Annouschka Laenen, Annick Bogaerts, Katrien Benhalima
Summary: This study aimed to identify risk factors for early postpartum weight retention (PPWR) and glucose intolerance (GI) in women with gestational diabetes (GDM). The results showed that excessive gestational weight gain, lack of breastfeeding, higher dietary fat intake, insulin use during pregnancy, multiparity, lower prepregnancy body mass index (BMI), and lower education degree were independent predictors for early PPWR. Women with high PPWR had a more impaired postpartum metabolic profile, breastfed less often, had higher rates of depression and anxiety, and lower quality of life. Additionally, 28% of participants had GI, with women with high PPWR being more likely to have GI. Only 12.9% of women with high PPWR perceived themselves at high risk for diabetes but were more willing to change their lifestyle.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Editorial Material
Endocrinology & Metabolism
Jacqueline Trouillas, Pia Burman, Marco Losa, Ann McCormack, Stephan Petersenn, Vera Popovic, Marily Theodoropoulou, Olaf M. Dekkers, Gerald Raverot
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Christophe De Block, Alice Y. Y. Cheng, Trine Brandt Christensen, Usha Rani H. Patted, Anna Ginovker
Summary: This study aimed to understand healthcare professionals' knowledge and attitudes towards the use of Time in Range (TIR) metric as well as the benefits and barriers to its use in clinical practice. The majority of healthcare professionals agreed that TIR is likely to become the standard of diabetes management and highlighted the importance of integrating TIR into clinical guidelines, recognition by regulators, and recognition by payers to increase its use.
Article
Endocrinology & Metabolism
Lore Raets, Lore Van Doninck, Paul Van Crombrugge, Carolien Moyson, Johan Verhaeghe, Sofie Vandeginste, Hilde Verlaenen, Chris Vercammen, Toon Maes, Els Dufraimont, Nele Roggen, Christophe De Block, Yves Jacquemyn, Farah Mekahli, Katrien De Clippel, Annick Van den Bruel, Anne Loccufier, Annouschka Laenen, Roland Devlieger, Chantal Mathieu, Katrien Benhalima
Summary: The study found that pregnant women with normal glucose tolerance (NGT) who had a glycemic value lower than 3.9 mmol/L during the oral glucose tolerance test (OGTT) had a higher risk of giving birth to a neonate with low birth weight.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Carlien De Herdt, Christophe De Block, Sven Francque, An Verrijken, Kristof Van Dessel, Luc Van Gaal, Jolijn Van Cauwenberghe, Eveline Dirinck
Summary: The purpose of this study was to investigate the association between testosterone and non-alcoholic fatty liver disease (NAFLD). A retrospective analysis was performed on obese men who underwent a liver biopsy and metabolic and hepatological work-up. Results showed no significant difference in testosterone levels between NAFLD and NASH, but a lower level of free testosterone was observed in higher stages of fibrosis, which can be explained by poor metabolic parameters.
Meeting Abstract
Gastroenterology & Hepatology
Laurens van Kleef, Sven Francque, Jhon Prieto-Ortiz, Milan Sonneveld, Carlos B. Sanchez Luque, Robin G. Prieto-Ortiz, Wilhelmus Kwanten, Luisa Vonghia, An Verrijken, Christophe De Block, Zouhir Gadi, Harry La Janssen, Robert De Knegt, Willem Pieter Brouwer
JOURNAL OF HEPATOLOGY
(2023)